Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Cell/Gene Tx channel feed
Spark loses another top exec in the wake of $4.3B takeover by Roche — report
6 years ago
People
'The headlines are the headlines, but': BioMarin talks up potential savings as hemophilia gene therapy launch looms
6 years ago
Will a 'risk-off' mindset hasten cell therapy M&A? Iovance surges on buyout chatter
6 years ago
Deals
Biogen touts new evidence from the gene therapy company it wagered $800M on
6 years ago
R&D
Speedy review and no adcomm for BioMarin's pioneering hemophilia gene therapy
6 years ago
FDA+
Gene therapy pioneer Kathy High has left Spark after completing $4.3B union with Roche
6 years ago
People
TCR-focused Immatics adds another marquee name to its list of partners: GSK
6 years ago
Deals
FDA slaps a hold on LogicBio and its gene editing plans — shares tumble
6 years ago
FDA+
From mice to dogs, and someday man: George Church's gene therapy cocktail for aging-related diseases
6 years ago
Startups
R&D
Kymriah pioneer Carl June is back, with first US human evidence for CRISPR use in cancer
6 years ago
MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner
6 years ago
R&D
How much does it cost to bootstrap a gene therapy startup? Not too much if you're Jim Wilson, per Passage Bio's $125M IPO filing
6 years ago
Financing
Catalent chief John Chiminski triggers a $315M-plus wager on the booming cell therapy market now in the making
6 years ago
Deals
Outsourcing
Resistant to CAR-T therapies? It's the cancer, not your immune system — study
6 years ago
R&D
Eyeing a trio of trial initiations, Jim Wilson's gene therapy startup woos Bruce Goldsmith from Deerfield as CEO
6 years ago
People
Deerfield vaults to the top of cell and gene therapy CDMO game with $1.1B facility at Philadelphia's newest biopharma hub
6 years ago
Outsourcing
At #JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell
6 years ago
R&D
In Focus
With $110M to add to the bankroll, Generation Bio sets its sights on engineering a revolution in the gene therapy field
6 years ago
Financing
Chinese court sentences Jiankui He to 3 years in jail — and confirms birth of 3rd CRISPR baby
6 years ago
China
Flagship bankrolls quest to create gene therapy 2.0, with new viral delivery tech in hand
6 years ago
Financing
Startups
Inside Astellas' $3B Audentes gene therapy acquisition: coded messages, a bidding war and $77M for the CEO
6 years ago
Deals
UK antitrust watchdog clears Roche/Spark deal — but what is the FTC thinking?
6 years ago
Deals
Jury finds Gilead liable for $585M and big royalties in Kite CAR-T patent case
6 years ago
Kite Pharma's ex-CEO contradicts founder as CAR-T patent trial heats up, with conflicting valuations
6 years ago
First page
Previous page
48
49
50
51
52
53
54
Next page
Last page